Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Great for you share4 to follow.
https://www.linkedin.com/company/physiomics-plc
That large chunk earlier on could have been from Paul, showing he has about 680k of shares.
An unknown buyer agreed to acquire DoseMeRx Solution of Tabula Rasa HealthCare, Inc.
https://simplywall.st/stocks/us/healthcare/nasdaq-trhc/tabula-rasa-healthcare
Hopefully whoever takes over Doseme-Rx will continue with Physiomics prostrate cancer project.
https://www.prnewswire.com/news-releases/tabula-rasa-healthcare-to-sell-dosemerx-301478115.html
Tabula Rasa HealthCare, Inc.® (TRHC) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, announced today that it has signed a non-binding Letter of Intent to sell its DoseMeRx solution.
"At our last earnings call, we noted that we were evaluating options to unlock value in non-core assets. This strategic divestiture underscores TRHC's commitment to sharpening our focus on our core mission, better positioning the company for growth and increased shareholder value," said TRHC Chairman and CEO, Calvin H. Knowlton, PhD. "Our search for the right partner to help further advance DoseMe's innovative solutions has been extensive, and we are encouraged by the interest and enthusiasm in the market for this excellent business and technology."
Orsula V. Knowlton, PharmD, MBA, Co-Founder and President at Tabula Rasa HealthCare
Rising healthcare costs and a growing elderly population could have significant implications when it comes to the safe use of medication. The risk of being harmed by medication, even when used as intended, is increasing because traditional approaches to medication safety are outdated and ignore simultaneous, multi-drug interactions, especially among patients who take numerous drugs. The old approaches leave patients at risk of harm that could be avoided. Unintentional harm from medication is responsible for 1.3 million emergency department visits a year.
Technology that supports advanced decision support systems for pharmacists and clinicians will be critical in advancing the safe use of medication in 2022. Medication management tools that enhance patient safety by identifying accumulative multi-drug interactions will be needed to shift the medication safety paradigm to personalization and proactive analysis, helping to prevent adverse drug events and save lives. Patients should not need to risk being harmed by their medications.
https://www.healthcareittoday.com/2022/02/01/final-2022-health-it-predictions/
Since 13th Jan, I make that 20 x 100k sells so far.
Are there going to be many more?
Blog on Pyc site by David Orwell about “ Quantum Pharma”.
https://www.physiomics.co.uk/quantum-pharma/
Happy New Year to everyone for 2022.
55 trade yesterday.
29 trade today.
RNS soon.
2021 has undoubtedly proven another tough year. Cancer services continue to be disrupted in the presence of covid-19, but as we look back over the last 12 months it’s great to count the progress that has been made.
At Physiomics plc, this includes new collaborations & partnerships, the chance to be involved in a number of pioneering projects and continuing our work to combat #cancer. Here are our 2021 highlights:
?? We were thrilled to start the year by announcing a new agreement with VALIRX PLC. This involves using our expertise in modelling the effects of prostate cancer treatment, and using the latest version of our Virtual Tumour™ tech to model the use of VAL201 in endometriosis (VAL301) and Coronavirus (BC201).
?? In April, we presented 2 new posters at #AACR21. The first poster, focusing on our first precision dosing tool, describes the additional functionality to model the co-administration of G-CSF to increase the utility of the tool during #COVID19. American Association for Cancer Research
?? We announced a new collaboration with Numab Therapeutics AG, an exciting young biopharmaceutical company based in Zurich who are developing novel antibody-based therapeutics for the treatment of chronic inflammation and cancer.
?? This year, we also announced additional contracts with Merck. We’re delighted that we’ll be continuing our long-term program of work to provide predictive modelling services using our continuously evolving Virtual Tumour™ technology.
?? We were also pleased to announce two new contracts with Bicycle Therapeutics relating to two of Bicycle’s lead clinical assets & building on our earlier work on BT1718, its lead programme currently in a Cancer Research UK (CRUK)-sponsored Phase I/2 clinical trial in advanced cancers.
?? We expanded our team! In July Dr Nathalie Dupuy joined our technical team as a Biosimulation Scientist. In Aug we were also pleased to announce that Hayley Close has joined our company as Head of Business Development.
?? In Sept, we were excited to announce that our NIHR (National Institute for Health Research)-funded PARTNER study has recruited its first patient! This is an observational clinical trial run by the Portsmouth Technology Trials Unit (PTTU). Read all about it here: https://bit.ly/2XY7POc Portsmouth Hospitals University NHS Trust University of Portsmouth
?? Last month we presented a poster at #SITC21, highlighting a recent project with Bicycle Therapeutics. This showcases how we developed a PK/PD modelling framework to explore dosing/scheduling for BT7480, the lead Bicycle tumour-targeted immune cell agonist.
?? ?? You can keep up with all our latest news by visiting our website and subscribing to our newsletter. Make sure to follow us on Twitter @Physiomics for all of our latest updates. You can view all our latest posters here ?? https://lnkd.in/dfEzcZng
Should have RNS soon, as agm was held at 10am.
Looks like a positive report from Simplywall St instead of usual negative.
Unable to read all unless being signed up to site.
https://simplywall.st/stocks/gb/pharmaceuticals-biotech/aim-pyc/physiomics-shares/news/heres-why-shareholders-will-not-be-complaining-about-physiom
Stock also being dealt on German market, been buys last 2 days.
https://www.marketscreener.com/search/?mots=Physiomics&RewriteLast=&noredirect=0&type_recherche=0
If we can break 6.8p, next step 7.6p.
Are we going to have a spate of low trades again like several months ago?
Not sure if there was any meaning to it then.
Reading on Val bb, went down very well, suggests deal by year end.
Numab therapeutics who is partnered with CStone Pharmaceuticals with product CS2006/NM21-1480 has gained approval in China.
https://finance.yahoo.com/news/cstone-received-china-nmpa-ind-003000820.html
One of their collaborators Bicycle therapeutics doing presentation this week.
https://uk.finance.yahoo.com/news/bicycle-therapeutics-present-bt5528-interim-203000794.html
https://www.physiomics.co.uk/wp-content/uploads/2021/09/Physiomics-Update-30-Sept-2021.pdf
Let’s see what is said/ announced later on.